Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-324 in Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer
NCT06858813Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2025
- Primary completion
- Sep 2030
- Countries
- 7
01
Overview
Phase 1, randomised, open-label trial of ABBV-324 in hepatocellular carcinoma (HCC) and squamous cell carcinoma of the lung (SCCL) (5 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events up to 4 years, Number of Participants with Change in Vital Signs up to 4 years and 3 more. Started Apr 2025; status: recruiting.
02
Drugs
ABBV-324
03
Conditions
hepatocellular carcinoma (HCC)squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT06858813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06858813.